Prot #NEU-411-PD201: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson’s Disease (NEULARK)

Project: Research project

Project Details

StatusActive
Effective start/end date2/5/25 → 2/5/28

Funding

  • Rho, Inc (Prot #NEU-411-PD201 // Prot #NEU-411-PD201)
  • Neuron23, Inc. (Prot #NEU-411-PD201 // Prot #NEU-411-PD201)